Tebipenem Pivoxil

Summary

Tebipenem Pivoxil (CHEMBL2107486) is a phase-3 clinical-stage small molecule (ATC J01DH06); indicated across 4 conditions including bacterial infectious disease and shigellosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: J01DH06
• Indications: 4 conditions
• Clinical trials: 1
• Chemistry: 497.6 Da · C22H31N3O6S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107486
Name	Tebipenem Pivoxil
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9892071
ATC	J01DH06
Molecular formula	C22H31N3O6S2
Molecular weight	497.6
InChIKey	SNUDIPVBUUXCDG-QHSBEEBCSA-N

SMILES: C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)OCOC(=O)C(C)(C)C)[C@@H](C)O

IUPAC name: 2,2-dimethylpropanoyloxymethyl (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

Also known as: L-084, LJC 11,084, LJC 11084, LJC-11084, ME-1211, ME1211, Orapenem, TBPM-PI, Tebipenem pivoxil, Tebipenem pivoxilo, TEBIPENEM PIVOXIL, SID174006193

Parent form; salt/anhydrous children: CHEMBL4297677

Patent coverage: 138 distinct patent families (345 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prolyl endopeptidase FAP.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FAP	6.19	Ki	640	nM	CHEMBL_ACT_29108083

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
bacterial infectious disease	3	MONDO:0005113	EFO:0000771
shigellosis	2	MONDO:0019345	EFO:0005585
kidney disorder	1	MONDO:0005240	EFO:0003086

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05121974	PHASE2	ACTIVE_NOT_RECRUITING	Tebipenem Trial in Children With Shigellosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).